Belvedere Trading
RAPT

Belvedere Trading’s RAPT Therapeutics RAPT Stock Holding History

Belvedere Trading’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300
Closed -$21.6K – 868
2024
Q1 		$21.6K Buy
+300
New +$41.7K ﹤0.01% 564
2023
Q2 		– Sell
-800
Closed -$117K – 1073
2023
Q1 		$117K Buy
+800
New +$162K ﹤0.01% 439

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Belvedere Trading's RAPT Position: Q2 2024 in Review

Belvedere Trading sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 111 shares — an estimated $7.96K sold.

Belvedere Trading first reported a position in RAPT in Q1 2023 and held it in 2 quarters. The position peaked at $47.1K in Q1 2023. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Belvedere Trading reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 111 RAPT Therapeutics shares in Q2 2024, an estimated $7.96K.
  • Belvedere Trading first reported a position in RAPT Therapeutics in Q1 2023 and held it in 2 quarters.
  • Belvedere Trading's RAPT Therapeutics position peaked at $47.1K in Q1 2023.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.